http://www.companiesandmarkets.com/S...ntroductionCRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.Scope*Examination of the CRC pipeline with in-depth clinical and commercial profiles of Phase III candidates*Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2018*Segmentation and analysis of the current CRC pipeline by developmental phase, drug class and
More...
More...